Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Federal Trade Commission
QuintilesIMS
Mallinckrodt
Johnson and Johnson
Medtronic
Argus Health
Julphar
Queensland Health

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020757

« Back to Dashboard

NDA 020757 describes AVAPRO, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from three suppliers. Additional details are available on the AVAPRO profile page.

The generic ingredient in AVAPRO is irbesartan. There are thirty-eight drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the irbesartan profile page.
Summary for 020757
Tradename:AVAPRO
Applicant:Sanofi Aventis Us
Ingredient:irbesartan
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020757
Suppliers and Packaging for NDA: 020757
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AVAPRO irbesartan TABLET;ORAL 020757 NDA sanofi-aventis U.S. LLC 0024-5850 N 0024-5850-30
AVAPRO irbesartan TABLET;ORAL 020757 NDA sanofi-aventis U.S. LLC 0024-5850 N 0024-5850-90

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength75MG
Approval Date:Sep 30, 1997TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength150MG
Approval Date:Sep 30, 1997TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength300MG
Approval Date:Sep 30, 1997TE:ABRLD:Yes

Expired US Patents for NDA 020757

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-002 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-001 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-003 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-003 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Accenture
Boehringer Ingelheim
Argus Health
Cipla
Johnson and Johnson
QuintilesIMS
Julphar
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.